291 related articles for article (PubMed ID: 34421401)
1. Abstract PS6-55: The prognostic utility of AR/ER ratio in young women with breast cancer.
Prabhu JS; Korlimarla A; Rajarajan S; Alexander A; Anupama C; Ramesh R; Srinath B; Sridhar TS
Cancer Res; 2021 Feb; 81(4 Suppl):. PubMed ID: 34421401
[TBL] [Abstract][Full Text] [Related]
2. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes.
Rajarajan S; Korlimarla A; Alexander A; Anupama CE; Ramesh R; Srinath BS; Sridhar TS; Prabhu JS
Front Endocrinol (Lausanne); 2021; 12():679756. PubMed ID: 34234742
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy.
Shi Z; Liu Y; Zhang S; Cai S; Liu X; Meng J; Zhang J
Discov Oncol; 2023 Apr; 14(1):49. PubMed ID: 37099044
[TBL] [Abstract][Full Text] [Related]
4. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.
Kensler KH; Poole EM; Heng YJ; Collins LC; Glass B; Beck AH; Hazra A; Rosner BA; Eliassen AH; Hankinson SE; Winer EP; Brown M; Tamimi RM
J Natl Cancer Inst; 2019 Jul; 111(7):700-708. PubMed ID: 30445651
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
7. Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
Jongen L; Floris G; Wildiers H; Claessens F; Richard F; Laenen A; Desmedt C; Ardui J; Punie K; Smeets A; Berteloot P; Vergote I; Neven P
Breast Cancer Res Treat; 2019 Aug; 176(3):699-708. PubMed ID: 31106385
[TBL] [Abstract][Full Text] [Related]
8. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
[TBL] [Abstract][Full Text] [Related]
9. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
10. The role of the AR/ER ratio in ER-positive breast cancer patients.
Rangel N; Rondon-Lagos M; Annaratone L; Osella-Abate S; Metovic J; Mano MP; Bertero L; Cassoni P; Sapino A; Castellano I
Endocr Relat Cancer; 2018 Mar; 25(3):163-172. PubMed ID: 29386247
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
12. Quadruple Negative Breast Cancers (QNBC) Demonstrate Subtype Consistency among Primary and Recurrent or Metastatic Breast Cancer.
Angajala A; Mothershed E; Davis MB; Tripathi S; He Q; Bedi D; Dean-Colomb W; Yates C
Transl Oncol; 2019 Mar; 12(3):493-501. PubMed ID: 30594038
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW; Lee KS
Ann Oncol; 2011 Aug; 22(8):1755-62. PubMed ID: 21310761
[TBL] [Abstract][Full Text] [Related]
14.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
15. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
[TBL] [Abstract][Full Text] [Related]
16. Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study.
Acs B; Hartman J; Sönmez D; Lindman H; Johansson ALV; Fredriksson I
Lancet Reg Health Eur; 2024 May; 40():100886. PubMed ID: 38745990
[TBL] [Abstract][Full Text] [Related]
17. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
18. Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers.
Park S; Park HS; Koo JS; Yang WI; Kim SI; Park BW
Breast Cancer Res Treat; 2012 May; 133(1):311-20. PubMed ID: 22231421
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.
Secreto G; Venturelli E; Meneghini E; Carcangiu ML; Paolini B; Agresti R; Pellitteri C; Berrino F; Gion M; Cogliati P; Saragò G; Micheli A
BMC Cancer; 2012 Dec; 12():599. PubMed ID: 23241075
[TBL] [Abstract][Full Text] [Related]
20. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Riaz N; Idress R; Habib S; Lalani EN
Front Oncol; 2020; 10():1083. PubMed ID: 32850312
[No Abstract] [Full Text] [Related]
[Next] [New Search]
